Jacobio Pharmaceuticals

Founded in 2015, Jacobio (Stock code: 1167.HK) is a leading biopharmaceutical company that focuses on developing innovative drugs with global intellectual property rights. Jacobio aims to target proteins that are difficult or impossible to drug with conventional approaches, and has significant clinical value. Their core technology, the "Induced Allosteric Drug Discovery Platform (IADDP)", integrates multiple proprietary techniques to identify potential allosteric sites, reveal novel allosteric mechanisms, design original allosteric molecules, and achieve the mission of "drugging the undruggable".

Investment time	2015
Incubation Successes	In 2015, Center Ventures invested in Dr. Yinxiang Wang, chairman of Jacobio Pharmaceuticals, and his team, becoming Jacobio Pharmaceuticals’ second largest shareholder with nearly 25% of the shares. Although Center Ventures’ equity was diluted through two rounds of fundraising, its shareholder value has increased tremendously per Series C valuation. Center Ventures' currently maintains a 10% equity stake in the company.
Milestones	In 2018, Jacobio’s first new drug JAB-3000 has started clinical studies in China and the U.S. Jacobio Pharmaceuticals raised US$55 million in Series C funding round. Successful launch and NRDL inclusion of Glecirasertib (KRAS G12C), initiating the commercial harvest phase. Global licensing of JAB-23E73 (pan-KRAS) to AstraZeneca for up to US$2 billion, including a US$100 million upfront payment.